THE LAWSUIT: A class action securities lawsuit was filed against Indivior PLC that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 22, ...

French biotechnology company specializing in the treatment of brain disorders Aelis Farma reported Wednesday the results from ...

THE LAWSUIT: A class action securities lawsuit was filed against Indivior PLC that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 22, ...

In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Indivior (INDV – Research Report), with a ...

Indivior has failed in its bid to prevent a lawsuit claiming that it illegally blocked competition to opioid addiction drug Suboxone from coming to court in the US.

Indivior had been guiding on sales of $990 million to $1.02 billion for the full year, and is sticking to that guidance until a launch in 2018 is certain, saying “the magnitude of the risk will ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Indivior (INDV – Research Report), with a price ...

BARDA purchased OPVEE, a nalmefene opioid overdose reversal nasal spray Through BARDA's contract with Indivior, communities will be better equipped to respond to mass poisoning emergencies and ...

Primary and Secondary End Points of the Study were Not Met Indivior Does Not Currently Expect to Exercise AEF0117 Option The results of the study demonstrated that the primary endpoint ...

On Friday, Piper Sandler affirmed its positive stance on Indivior (NASDAQ: INDV), maintaining an Overweight rating and a $22.00 price target for the pharmaceutical company's stock. The firm's analysis ...